Ksg 504 | CAS#137005-17-5 | CCK-A receptor antagonist

MedKoo Cat#: 584532 | Name: Ksg 504

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ksg 504 has superior selectivity and affinity to CCK-A receptors and derived from proglumide.

Chemical Structure

Ksg 504

CAS#137005-17-5

Theoretical Analysis

MedKoo Cat#: 584532

Name: Ksg 504

CAS#: 137005-17-5

Chemical Formula: C31H49N5O8S

Exact Mass: 651.3302

Molecular Weight: 651.82

Elemental Analysis: C, 57.12; H, 7.58; N, 10.74; O, 19.64; S, 4.92

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Ksg 504; Ksg504; Ksg-504

IUPAC/Chemical Name

L-Arginine, mono((R)-5-((3-methoxypropyl)pentylamino)-4-((2-naphthalenylsulfonyl)methyl)-5-oxopentanoate)

InChi Key

TXTJVOOURRNANH-QEXBQMGZSA-N

InChi Code

InChI=1S/C25H35NO6S.C6H14N4O2/c1-3-4-7-15-26(16-8-17-32-2)25(29)22(12-14-24(27)28)19-33(30,31)23-13-11-20-9-5-6-10-21(20)18-23;7-4(5(11)12)2-1-3-10-6(8)9/h5-6,9-11,13,18,22H,3-4,7-8,12,14-17,19H2,1-2H3,(H,27,28);4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t22-;4-/m00/s1

SMILES Code

N[C@@H](CCCNC(N)=N)C(O)=O.O=C(O)CC[C@@H](CS(=O)(C1=CC=C2C=CC=CC2=C1)=O)C(N(CCCOC)CCCCC)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 651.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Okumura Y, Inoue H, Fujiyama Y, Bamba T. Effects of short-term administration of the CCK receptor antagonist, KSG-504, on regeneration of pancreatic acinar cells in acute pancreatitis in rats. J Gastroenterol. 1995 Aug;30(4):493-9. PubMed PMID: 7550860. 2: Takács T, Czakó L, Jármay K, Farkas G Jr, Mándi Y, Lonovics J. Cytokine level changes in L-arginine-induced acute pancreatitis in rat. Acta Physiol Hung. 1996;84(2):147-56. PubMed PMID: 9046361. 3: Moriyoshi Y, Shiratori K, Takeuchi T, Watanabe S. A new CCK-A antagonist, KSG-504, administered intraduodenally, inhibits pancreatic secretion in rats. Pancreas. 1994 Mar;9(2):225-9. PubMed PMID: 8190724. 4: Yamazaki Y, Takeda H, Akahane M, Tsubaki A, Ajisawa Y. [Behavioral studies of KSG-504, a new CCK-A receptor antagonist]. Nihon Yakurigaku Zasshi. 1996 Jan;107(1):21-31. Japanese. PubMed PMID: 8720295. 5: Ha S, Satake K, Hiura A, Sowa M, Nishiwaki H. Effect of a new cholecystokinin receptor antagonist (KSG 504) on the early stage of the healing process in acute pancreatitis induced in rats by the closed duodenal loop technique. Pancreas. 1994 Jul;9(4):501-7. PubMed PMID: 7524065. 6: Yamazaki Y, Akahane M, Kobayashi M, Shinagawa K, Sugiura M, Ajisawa Y. [Effects of KSG-504, a new CCK-A receptor antagonist, on gallbladder and gastrointestinal functions]. Nihon Yakurigaku Zasshi. 1996 Jan;107(1):33-44. Japanese. PubMed PMID: 8720296. 7: Kihara Y, Otsuki M. Different inhibitory effects of the newly developed CCK receptor antagonists FK480 and KSG-504 on pancreatic exocrine and endocrine secretion in the isolated perfused rat pancreas. Pancreas. 1995 Mar;10(2):109-17. PubMed PMID: 7716133. 8: Yamazaki Y, Akahane M, Kobayashi M, Kitazawa M, Kurashina Y, Iizuka K. Pharmacological profile of KSG-504, a new cholecystokinin-A-receptor antagonist. Jpn J Pharmacol. 1993 Oct;63(2):219-25. PubMed PMID: 7506805. 9: Okumura Y, Bamba T, Shintani Y, Yoshioka U, Inoue H, Fujiyama Y, Hosoda S. [Effect of KSG-504, a new synthetic cholecystokinin receptor antagonist on ethionine-induced acute pancreatitis in rats]. Nihon Shokakibyo Gakkai Zasshi. 1993 Dec;90(12):3032-40. Japanese. PubMed PMID: 8283814. 10: Yamazaki Y, Shinagawa K, Takeda H, Kobayashi M, Akahane M, Ajisawa Y. Cholecystokinin-A specific antagonism of KSG-504 to cholecystokinin receptor binding and pancreatic secretion in mammals. Jpn J Pharmacol. 1995 Dec;69(4):367-73. PubMed PMID: 8786640. 11: Czakó L, Takács T, Varga IS, Hai DQ, Tiszlavicz L, Hegyi P, Mándi Y, Matkovics B, Lonovics J. The pathogenesis of L-arginine-induced acute necrotizing pancreatitis: inflammatory mediators and endogenous cholecystokinin. J Physiol Paris. 2000 Jan-Feb;94(1):43-50. PubMed PMID: 10761688. 12: Yamazaki Y, Akahane M, Kobayashi M, Takeda H, Ajisawa Y. Effects of KSG-504, a new cholecystokinin-A-receptor antagonist, on pancreatic exocrine and endocrine secretions in rats. Jpn J Pharmacol. 1996 Feb;70(2):183-90. PubMed PMID: 8866756. 13: Kobayashi M, Shinagawa K, Sugiura M, Nagasawa T, Akahane M, Ajisawa Y. [Effect of KSG-504, a new CCK-A-receptor antagonist, on experimental acute pancreatitis in rats and mice]. Nihon Yakurigaku Zasshi. 1996 Apr;107(4):183-95. Japanese. PubMed PMID: 8690301.